http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Stem cell-based therapy for inflammatory bowel disease
Hiromichi Shimizu,Kohei Suzuki,Mamoru Watanabe,Ryuichi Okamoto 대한장연구학회 2019 Intestinal Research Vol.17 No.3
Inflammatory bowel disease (IBD) is an idiopathic, multi-etiological disease characterized by inflammation and mucosal destruction of the gastrointestinal tract. Despite the remarkable advance in immunomodulating therapies, there still remains a certain population of patients who are refractory to conventional as well as biologic therapies and fail to achieve mucosal healing. To improve the prognosis of those patients, at least 2 types of stem cells have been tested for their potential therapeutic use. Transplantation of hematopoietic stem cells or mesenchymal stem cells have been tested in several clinical studies, but their beneficial effect still remains controversial. In this review, we would like to overview the recent clinical challenges of stem cell-based therapies in IBD and also introduce our new therapeutic plan of intestinal stem cell transplantation for IBD, based on our ex vivo intestinal organoid culture technique.
Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis
( Hiromichi Shimizu ),( Toshimitsu Fujii ),( Shuji Hibiya ),( Maiko Motobayashi ),( Kohei Suzuki ),( Kento Takenaka ),( Eiko Saito ),( Masakazu Nagahori ),( Kazuo Ohtsuka ),( Mamoru Watanabe ) 대한장연구학회 2021 Intestinal Research Vol.19 No.1